Figure 6

HDAC10^−/− Treg cells improve autoimmune colitis outcomes. (A–C) Autoimmune colitis rescue model: B6/Rag1^−/− mice were adoptively transferred with 1 × 10⁶ wild type (WT) CD4⁺CD25⁻ Tconv i.p. (day 0), and were closely monitored for weight loss. On day 33 after adoptive transfer of the Tconv, the mice received 5 × 10⁵ CD4⁺CD25⁺ Treg from either WT or HDAC10^−/− (H10^−/−) mice i.p. (A) Weight tracking of B6/Rag1^−/− mice receiving Treg from either WT or HDAC10^−/− donors. (B,C) At the end of the experiment (day 139), HDAC10^−/− Treg recipients showed a trend to less splenocyte counts (B) and longer colon length (C), however, significance was missed (Mann Whitney test, 5–6 mice per group). (D–H) Autoimmune colitis prevention model: B6/Rag1^−/− mice were adoptively transferred i.p. with 1 × 10⁶ wild type (WT) CD4⁺CD25⁻ Tconv together with 5 × 10⁵ CD4⁺CD25⁺ Treg from either WT or HDAC10^−/− donors. (D) B6/Rag1^−/− mice receiving HDAC10^−/− Treg developed less weight loss (unpaired Student t-test, 10/group). (E,F) HDAC10^−/− Treg recipients exhibited less smaller spleens. (E) Shows representative photograph, (F) splenocyte counts (unpaired Student t-test). (G,H) HDAC10^−/− Treg recipients were found to have longer colons. (G) Representative photograph, (H) colon measurements (unpaired Student t-test). Data shown as mean ± SEM (A,F,H), median ± IQR (B,C), and individual replicates (D).